Selected article for: "active rheumatoid arthritis and tumor necrosis factor"

Author: Robinson, Philip C.; Liew, David F.L.; Liew, Jean W.; Monaco, Claudia; Richards, Duncan; Shivakumar, Senthuran; Tanner, Helen L.; Feldmann, Marc
Title: The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19
  • Cord-id: todnws9r
  • Document date: 2020_12_3
  • ID: todnws9r
    Snippet: Coronavirus disease 2019 (COVID-19) currently has few effective treatments. Given the uncertainty surrounding the effectiveness and uptake of a vaccine, it is important that the search for treatments continue. An exaggerated inflammatory state is likely responsible for much of the morbidity and mortality in COVID-19. Elevated levels of tumor necrosis factor (TNF), a key pro-inflammatory cytokine, have been shown to be associated with increased COVID-19 mortality. In patients with rheumatoid arth
    Document: Coronavirus disease 2019 (COVID-19) currently has few effective treatments. Given the uncertainty surrounding the effectiveness and uptake of a vaccine, it is important that the search for treatments continue. An exaggerated inflammatory state is likely responsible for much of the morbidity and mortality in COVID-19. Elevated levels of tumor necrosis factor (TNF), a key pro-inflammatory cytokine, have been shown to be associated with increased COVID-19 mortality. In patients with rheumatoid arthritis, TNF blockade reduces not only biologically active TNF but other pro-inflammatory cytokines important in COVID-19 hyperinflammation. Observational data from patients already on anti-TNF therapy show a reduced rate of COVID-19 poor outcomes and death compared with other immune-suppressing therapies. Anti-TNF has a long history of safe use, including in special at-risk populations, and is widely available. The case to adequately assess anti-TNF as a treatment for COVID-19 is compelling.

    Search related documents:
    Co phrase search for related documents
    • Try single phrases listed below for: 1